Immunocore Holdings plc (IMCR)
NASDAQ: IMCR · Real-Time Price · USD
30.49
-0.78 (-2.49%)
Oct 30, 2026, 4:00 PM EDT - Market closed
Immunocore Holdings Employees
Immunocore Holdings had 524 employees as of December 31, 2025. The number of employees increased by 31 or 6.29% compared to the previous year. That makes Immunocore Holdings the 19,709th largest employer in the world and 2,652nd in the United States.
Employees
524
Change (1Y)
31
Growth (1Y)
6.29%
Revenue / Employee
$822,090
Profits / Employee
-$34,492
Market Cap
1.57B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 524 | 31 | 6.29% |
| Dec 31, 2024 | 493 | -4 | -0.80% |
| Dec 31, 2023 | 497 | 89 | 21.81% |
| Dec 31, 2022 | 408 | 84 | 25.93% |
| Dec 31, 2021 | 324 | 33 | 11.34% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Novavax | 749 |
| Replimune Group | 465 |
| Ocular Therapeutix | 325 |
| UroGen Pharma | 300 |
| Structure Therapeutics | 281 |
| Innoviva | 159 |
| Nanobiotix | 98 |
IMCR News
- 3 days ago - Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting - GlobeNewsWire
- 3 days ago - Immunocore price target lowered to $33 from $35 at Mizuho - TheFly
- 17 days ago - Immunocore doses first patient in IMC-S118AI trial - TheFly
- 17 days ago - Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes - GlobeNewsWire
- 6 weeks ago - Immunocore Holdings Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 6 weeks ago - Immunocore achieves target patient enrollment in TEBE-AM clinical trial - TheFly
- 6 weeks ago - Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma - GlobeNewsWire
- 7 weeks ago - Immunocore Holdings Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts